- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00044083
Clinical Trial of Tolcapone for Cognition in Schizophrenia
August 22, 2018 updated by: National Institute of Mental Health (NIMH)
Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Tolcapone and Entacapone on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype
This study will evaluate whether Tolcapone improves cognition in healthy volunteers as well as patients with schizophrenia. Talcapone is a drug that has been FDA approved for Attention Deficit Disorder and allegedly increase the amount of the neurotransmitter dopamine in the frontal cortex of the brain.
...
Study Overview
Detailed Description
Psychopharmacological modulation of the catecholaminergic system can enhance some aspects of cognitive function.
For example, COMT inhibitors can slightly improve working memory/executive function.
Differences in the response between individuals might be related to a number of factors, including variations in the genes.
The recent finding that a polymorphism in the catechol-o-methyl-transferase (COMT) gene, which produces a 4 fold change in enzyme activity, accounts for 4 percent of the variance in performance of working memory tasks in humans suggest that COMT genotype may predict response to COMT inhibitors.
In the present investigation our goal is to examine, in normal controls and patients with schizophrenia, the effect of a centrally acting (tolcapone) and of a peripherally acting (entacapone) COMT inhibitor on cognitive function.
We predict that both normal controls and patients with schizophrenia with the val/val genotype will have a significant, though transient, improvement in working memory in subjects treated with tolcapone but not in those treated with entacapone.
Furthermore, in conjunction with other NIMH imaging protocols, we would like to examine the neurophysiological correlates related to working memory.
We predict, in tolcapone treated subjects, improved measures in prefrontal 'efficiency' in subjects and patients specifically with the val/val genotype.
The present protocol will provide new insights on the importance of this genetic polymorphism in the regulation of aminergic-controlled cognitive function in normal individuals.
Furthermore, this protocol will test whether COMT inhibitors offer a new treatment-based on genotype - for cognitive impairment in schizophrenia.
No IND is required for the present study.
Study Type
Interventional
Enrollment (Actual)
210
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
INCLUSION CRITERIA:
- Prior participation under NIH protocol number 95-M-0150, or new normal volunteers or schizophrenic patients that meet criteria for NIH protocol number 95-M-0150 (NCT00001486).
- No Axis I or Axis II diagnosis in normal volunteers.
- Age range: 18-50 years.
EXCLUSION CRITERIA:
- Normal volunteers with an Axis I or Axis II disorder obtained either from prior SCID interview in Protocol 95-M-0150 or through a screening interview will be excluded.
- Subjects with a history of cardiovascular disease, liver disease and other medical illnesses, and untreated or uncontrolled hypertension will be excluded. An electrocardiogram, blood pressure, pulse rate and metabolic panel including LFTs will be checked on all subjects prior to participation in the study. Individuals with persistent tardive dyskinesia or abnormal LFTs, or individuals with significant history of alcoholism or liver enzyme elevation will be excluded from the study.
- Schizophrenic patients taking clozapine, a COMT inhibitor, any illicit drugs of abuse, or MAO inhibitors will be excluded.
- Normal control subjects taking any medications other than occasional NSAI will be excluded.
- Pregnant women. Women of childbearing potential will undergo a urine pregnancy test the day the study initiates and screened by history for the possibility of pregnancy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo Arm
Placebo one week
|
Placebo: One capsule 3 times a day from Day 1 to Day 7
|
Active Comparator: Tolcapone Arm
Tolcapone one week
|
Tolcapone: One capsule 3 times a day from Day 1 to Day 7
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
N-Back Task Performance
Time Frame: At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)
|
Working Memory was measured in HVs and patients with schizophrenia after a 7-day treatment with Tolcapone or placebo in a double-blind, cross-over fashion.
The working memory was quantified by taking the number of trials entered correctly divided by the total number of trials multiplied by 100.
Values range from 0 to 100.
Zero indicates the poorest performance while 100 indicates perfect performance.
|
At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)
|
N-Back Task Activation Diagnosis Effect
Time Frame: At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)
|
Activation beta values (N-Back vs. 0-Back) were extracted within the Main Effect of Diagnosis cluster around the peak (p < 0.05 uncorrected) from the contrast maps in the Placebo condition.
Lower beta values reflect more efficient processing in the DLPFC when performing working memory tasks.
|
At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)
|
N-Back Task Activation Drug Effect
Time Frame: At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)
|
Activation beta values (N-Back vs. 0-Back) extracted within the Main Effect of Drug cluster around the peak (p < 0.05 uncorrected) from the contrast maps across both groups.
Lower beta values reflect more efficient processing in the DLPFC when performing working memory tasks.
|
At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)
|
N-Back Task Activation in DLPFC in Patients With Schizophrenia
Time Frame: At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)
|
Activation Beta values (N-Back vs. 0-Back) extracted within the Effect of Drug cluster around the peak (p < 0.05 uncorrected) from the contrast maps in patients with schizophrenia.
Lower beta values reflect more efficient processing in the DLPFC when performing working memory tasks.
|
At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)
|
N-Back Task Activation in Healthy Volunteers
Time Frame: At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)
|
Activation Beta values (N-Back vs. 0-Back) extracted within the Effect of Drug cluster around the peak (p < 0.05 uncorrected) from the contrast maps in Healthy Volunteers.
Lower beta values reflect more efficient processing in the DLPFC when performing working memory tasks.
|
At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)
|
N-Back Task Activation Genotype Effect in Healthy Volunteers
Time Frame: At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)
|
Activation beta values (N-Back vs. 0-Back) extracted within the Effect of Genotype cluster around the peak (p < 0.05 uncorrected) in right and left DLPFC from the contrast maps in Healthy Volunteers.
Lower beta values reflect more efficient processing in the DLPFC when performing working memory tasks.
|
At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)
|
N-Back Task Activation by Genotype in Patients With Schizophrenia
Time Frame: At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)
|
Activation beta values (N-Back vs. 0-Back) extracted from DLPFC from the contrast maps in Patients with schizophrenia.
Lower beta values reflect more efficient processing in the DLPFC when performing working memory tasks.
|
At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Positive and Negative Syndrome Scale
Time Frame: At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)
|
Rating Scales PANSS.
The Positive Scale ranges for 7 to 49 with a higher score indicating greater severity of symptoms.
The Negative Scale ranges for 7 to 49 with a higher score indicating greater severity of symptoms.
The General Scale ranges from 16 to 112, the higher score indicating greater severity of symptoms.
|
At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jose A Apud, M.D., National Institute of Mental Health (NIMH)
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Aksoy S, Klener J, Weinshilboum RM. Catechol O-methyltransferase pharmacogenetics: photoaffinity labelling and western blot analysis of human liver samples. Pharmacogenetics. 1993 Apr;3(2):116-22. doi: 10.1097/00008571-199304000-00008.
- Andreasen NC, Arndt S, Cizadlo T, O'Leary DS, Watkins GL, Ponto LL, Hichwa RD. Sample size and statistical power in [15O]H2O studies of human cognition. J Cereb Blood Flow Metab. 1996 Sep;16(5):804-16. doi: 10.1097/00004647-199609000-00005.
- Arnsten AF. Catecholamine regulation of the prefrontal cortex. J Psychopharmacol. 1997;11(2):151-62. doi: 10.1177/026988119701100208.
- Magalona SC, Rasetti R, Chen J, Chen Q, Gold I, Decot H, Callicott JH, Berman KF, Apud JA, Weinberger DR, Mattay VS. Effect of tolcapone on brain activity during a variable attentional control task: a double-blind, placebo-controlled, counter-balanced trial in healthy volunteers. CNS Drugs. 2013 Aug;27(8):663-73. doi: 10.1007/s40263-013-0082-x.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2002
Primary Completion (Actual)
December 1, 2015
Study Completion (Actual)
December 1, 2015
Study Registration Dates
First Submitted
August 16, 2002
First Submitted That Met QC Criteria
August 16, 2002
First Posted (Estimate)
August 19, 2002
Study Record Updates
Last Update Posted (Actual)
September 27, 2018
Last Update Submitted That Met QC Criteria
August 22, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 020239
- 02-M-0239 (Other Identifier: Clinicaltrials.gov)
- NCT00044083 (Other Identifier: Clinicaltrials.gov)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
No plan to share data
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States